Navigation Links
UGA scientists unravel 'molecular inch-worm' structure of walking-pneumonia bacterium

Researchers at the University of Georgia, using glow-in-the-dark proteins and microcinematography, have helped unravel the development and function of a complex organelle in the bacterium that causes "walking pneumonia."

The researchers have described in new, precise detail the unique cell extension that forms on one end of the bacterium Mycoplasma pneumoniae. This structure, called a "terminal organelle," performs several tasks for this pervasive bacterium and even acts as a "molecular inch-worm," helping the microorganism move.

"Mycoplasmas are among the simplest known prokaryotes--only a fraction the size of other health-related bacteria such as E. coli," said microbiologist Duncan Krause, leader of the research team. "They are true minimalists with very small genomes, lacking the typical cell regulatory mechanisms found in other bacteria. And yet some species such as M. pneumoniae posses this complex terminal organelle. We've been able to observe it in growing cultures and describe the choreography of events at a level of detail not previously possible."

The research is being published this week in The Proceedings of the National Academy of Sciences. Other authors of the paper include graduate student Benjamin Hasselbring, undergraduate Robert Krause and former graduate student Jarrat Jordan.

M. pneumoniae infections affect millions worldwide, causing chronic bronchitis and atypical or "walking pneumonia," a term that describes cases of pneumonia that are distinct from acute, life-threatening pneumonia requiring a patient's hospitalization.

Krause and others have been increasingly interested in the terminal organelle that develops on one end of M. pneumoniae because it is involved in cell division, adherence to respiratory tissues and a little-understood mechanism of propulsion called "gliding motility."

Bacteria can move in a variety of ways, including the use of flagella to "swim." But since M. pneumoniae l ack flagella, they "glide," a method of movement that has been known for some time yet never entirely understood. The cells seem to bend and flex, but it's unclear how that is accomplished. The new data indicate that gliding is essential for cell division in M. pneumoniae.

"In addition to its significant impact on public health, M. pneumoniae is intriguing from a biological perspective," said Krause. "They have no cell walls, and their genome is among the smallest known for a cell capable of a free-living existence."

Other researchers, using electron microscopy, have described the basic structure of the terminal organelle, but Krause's team went further, using fluorescence microscopy and fluorescent protein fusions that allowed them to track the actions of specific proteins in live, growing cells. Time-lapse digital imaging let them see the development and activity of this structure in real time--giving new clues about function and demonstrating that, contrary to previous thinking, multiple new terminal organelles often form before cell division is observed.

From the standpoint of basic science, this research demonstrates the feasibility of using fluorescent proteins to study how organelles in these incredibly tiny bacteria grow and what their functions are. From a medical standpoint, however, they point the way to potential new drug targets and therapies to stop walking pneumonia and chronic bronchitis infections in their tracks.

Since the organelle is involved in colonization of epithelial tissues in human lungs, finding a way to stop such attachment or gliding could halt infections or make them far less severe.

"M. pneumoniae accounts for 20 percent of community-acquired pneumonias in this country," said Krause. "Finding out more about how the bacterium that causes the disease works gives us a new edge in thinking of ways to overcome such infections."


Source:University of Georgia

Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
3. UAB scientists discover the origin of a mysterious physical force
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
6. U-M scientists find genes that control growth of common skin cancer
7. UCLA scientists transform HIV into cancer-seeking missile
8. RNA project to create language for scientists worldwide
9. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
10. To control germs, scientists deploy tiny agents provocateurs
11. Leprosy microbes lead scientists to immune discovery
Post Your Comments:

(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology: